• [[ Whitepaper ]] Connecting With Rare Disease Patient Communities: Patient Advocates

    laureng Whitepapers April 19, 2018
  • [[Whitepaper ]] Disruptive Innovation in Rare Disease Markets

    laureng Whitepapers April 19, 2018
  • Choosing the Right Channel Strategy for Specialty Product Success

    Karina Kusova Clinical Development, Market Access, Orphan Drug Congress, Supply Chain & Manufacturing, Uncategorized, Whitepapers May 3, 2017
  • [Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies

    Karina Kusova Clinical Development, Orphan Drug Congress, Uncategorized, Whitepapers April 10, 2017
  • [[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches

    Karina Kusova Clinical Development, Featured on App, Orphan Drug Congress, Uncategorized, Whitepapers April 6, 2017
  • What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)

    Karina Kusova Advocacy, Clinical Development, Market Access, Orphan Drug Congress, Orphan Drugs Live October 10, 2016

Subscribe to Total Orphan Drugs

Strategy and innovation in the orphan drugs and rare diseases industry
Navigation
  • Development
  • Regulation
  • Advocacy
  • Market Access
  • Partnering & Investment
  • Whitepapers
  • Events
    • USA
  • Search
CNS

Tag Archive

View Post

SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

In Press Release by CameronJuly 23, 2014Leave a Comment

Designation Underscores Unmet Medical Need for Life-Threatening Seizure Condition July 22, 2014 SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central …

View Post

Lundbeck Completes Acquisition of Chelsea Therapeutics

In Press Release by CameronJune 27, 20141 Comment

NORTHERA™ (droxidopa) is expected to be available to patients in the U.S. during the fall of this year June 24, 2014 H. Lundbeck A/S (Lundbeck) …

View Post

SAGE Therapeutics Appoints Howard H. Pien to the Company’s Board of Directors

In Press Release by CameronApril 1, 2014Leave a Comment

Pien Brings Expansive Commercial Expertise to SAGE’s Rapidly Advancing Pipeline April 1, 2014 SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare …

SAGE Therapeutics Closes $38M Oversubscribed Series C Financing

In Press Release by CameronMarch 13, 2014Leave a Comment

March 13, 2014 SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the …

View Post

Third Rock Ventures Launches Voyager Therapeutics with $45 Million Series A to Develop Life-Changing Gene Therapies for CNS Disorders

In Press Release by CameronFebruary 17, 2014Leave a Comment

February 12, 2014 Third Rock Ventures, LLC announced the formation of Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the …

Categories

  • Advocacy
  • Clinical Development
  • Featured on App
  • Market Access
  • Orphan Drug Congress
  • Orphan Drugs Live
  • Partnering & Investment
  • Press Release
  • Regulation & Government
  • Reports
  • Supply Chain & Manufacturing
  • Uncategorized
  • Whitepapers
Toggle the Widgetbar
World Orphan Drug Congress USA
  • Home
  • About Us/Advertise